New study probes hidden blood risks in heart pump patients

NCT ID NCT06487091

Completed Knowledge-focused Sponsor: Università Vita-Salute San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined how the Impella heart pump changes platelet function in 30 patients with cardiogenic shock or cardiac arrest. Researchers measured markers of platelet activation and aggregation before and during pump support. The goal was to understand why some patients develop serious complications like bleeding or clots, and to find ways to identify high-risk individuals early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors identify patients at high risk of bleeding or clotting while on an Impella pump, leading to better monitoring and personalized treatments.
What could go wrong: This is a small, observational study with only 30 participants, so findings may not apply to all patients. It is exploratory and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC ARREST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac arrest cardiogenic shock Hemorrhage Shock, Cardiogenic thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC ARREST CARDIOGENIC SHOCK MECHANICAL CIRCULATORY SUPPORT

Contacts and locations

Locations

IRCCS San Raffaele Hospital

Milan, 20132, Italy
Università Vita Salute San Raffaele

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.